Paragon Associates & Paragon Associates II Joint Venture Increases Stake in DiaMedica Therapeutics, Inc. $DMAC

Paragon Associates & Paragon Associates II Joint Venture increased its stake in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) by 34.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 875,000 shares of the company’s stock after purchasing an additional 225,000 shares during the quarter. DiaMedica Therapeutics makes up about 10.7% of Paragon Associates & Paragon Associates II Joint Venture’s portfolio, making the stock its 4th largest holding. Paragon Associates & Paragon Associates II Joint Venture’s holdings in DiaMedica Therapeutics were worth $6,011,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Corient IA LLC acquired a new stake in DiaMedica Therapeutics in the third quarter valued at approximately $910,000. Rhumbline Advisers grew its stake in shares of DiaMedica Therapeutics by 14.5% during the third quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock worth $188,000 after buying an additional 3,463 shares during the last quarter. Meridian Wealth Management LLC increased its holdings in shares of DiaMedica Therapeutics by 89.1% during the third quarter. Meridian Wealth Management LLC now owns 51,666 shares of the company’s stock worth $355,000 after buying an additional 24,350 shares in the last quarter. Strs Ohio lifted its stake in shares of DiaMedica Therapeutics by 19.7% in the 3rd quarter. Strs Ohio now owns 9,100 shares of the company’s stock valued at $63,000 after acquiring an additional 1,500 shares during the last quarter. Finally, World Investment Advisors lifted its stake in shares of DiaMedica Therapeutics by 7.3% in the 3rd quarter. World Investment Advisors now owns 34,325 shares of the company’s stock valued at $236,000 after acquiring an additional 2,350 shares during the last quarter. Institutional investors own 10.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DMAC shares. Cantor Fitzgerald began coverage on DiaMedica Therapeutics in a report on Friday, November 14th. They set an “overweight” rating on the stock. Wall Street Zen cut DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Finally, Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC opened at $7.71 on Friday. The company’s 50 day moving average price is $8.21 and its 200-day moving average price is $7.52. DiaMedica Therapeutics, Inc. has a 52-week low of $3.19 and a 52-week high of $10.42. The company has a market capitalization of $401.54 million, a P/E ratio of -10.86 and a beta of 1.09.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.